SI1075264T1 - New drug combinations of reboxetine and pindolol - Google Patents

New drug combinations of reboxetine and pindolol

Info

Publication number
SI1075264T1
SI1075264T1 SI9930716T SI9930716T SI1075264T1 SI 1075264 T1 SI1075264 T1 SI 1075264T1 SI 9930716 T SI9930716 T SI 9930716T SI 9930716 T SI9930716 T SI 9930716T SI 1075264 T1 SI1075264 T1 SI 1075264T1
Authority
SI
Slovenia
Prior art keywords
reboxetine
pindolol
disorders
new drug
drug combinations
Prior art date
Application number
SI9930716T
Other languages
English (en)
Slovenian (sl)
Inventor
Duncan Paul Taylor
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of SI1075264T1 publication Critical patent/SI1075264T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SI9930716T 1998-05-08 1999-04-14 New drug combinations of reboxetine and pindolol SI1075264T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (1)

Publication Number Publication Date
SI1075264T1 true SI1075264T1 (en) 2005-06-30

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9930716T SI1075264T1 (en) 1998-05-08 1999-04-14 New drug combinations of reboxetine and pindolol

Country Status (22)

Country Link
EP (1) EP1075264B1 (ko)
JP (1) JP2002514601A (ko)
KR (1) KR20010052319A (ko)
CN (1) CN1300217A (ko)
AT (1) ATE283694T1 (ko)
AU (1) AU764579B2 (ko)
BR (1) BR9909559A (ko)
CA (1) CA2326105A1 (ko)
DE (1) DE69922367T2 (ko)
EA (1) EA003469B1 (ko)
ES (1) ES2232128T3 (ko)
HU (1) HUP0101341A3 (ko)
IL (1) IL139211A0 (ko)
NO (1) NO20005621D0 (ko)
NZ (1) NZ508035A (ko)
PL (1) PL345351A1 (ko)
PT (1) PT1075264E (ko)
SI (1) SI1075264T1 (ko)
SK (1) SK14502000A3 (ko)
TR (1) TR200003262T2 (ko)
WO (1) WO1999058130A1 (ko)
ZA (1) ZA200005301B (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1500395B1 (en) * 1999-07-01 2006-03-08 Pharmacia & Upjohn Company LLC Reboxetine for treating fibromyalgia and other somatoform disorders
PT1632234E (pt) 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
EP1723957A3 (en) 2002-12-27 2013-01-23 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP2429514A1 (en) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ES2145977T3 (es) * 1995-08-16 2000-07-16 Lilly Co Eli Potenciacion de la respuesta de la serotonina.

Also Published As

Publication number Publication date
BR9909559A (pt) 2000-12-19
EA003469B1 (ru) 2003-06-26
ATE283694T1 (de) 2004-12-15
WO1999058130A1 (en) 1999-11-18
EP1075264A1 (en) 2001-02-14
JP2002514601A (ja) 2002-05-21
HUP0101341A2 (hu) 2001-08-28
CN1300217A (zh) 2001-06-20
PL345351A1 (en) 2001-12-17
AU764579B2 (en) 2003-08-21
NO20005621L (no) 2000-11-07
AU3546099A (en) 1999-11-29
KR20010052319A (ko) 2001-06-25
PT1075264E (pt) 2005-01-31
EA200001162A1 (ru) 2001-04-23
ZA200005301B (en) 2001-10-01
DE69922367D1 (de) 2005-01-05
HUP0101341A3 (en) 2006-07-28
DE69922367T2 (de) 2005-12-22
ES2232128T3 (es) 2005-05-16
IL139211A0 (en) 2001-11-25
CA2326105A1 (en) 1999-11-18
SK14502000A3 (sk) 2001-05-10
EP1075264B1 (en) 2004-12-01
NZ508035A (en) 2004-02-27
TR200003262T2 (tr) 2001-03-21
NO20005621D0 (no) 2000-11-07

Similar Documents

Publication Publication Date Title
RS20120158A3 (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
DE60020613D1 (de) (S,S)-Reboxetin zur Behandlung von Fibromyalgie und anderen somatoformen Störungen
NO20064277L (no) 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister
HK1089177A1 (en) Modulators of peripheral 5-ht receptors
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
SI1075264T1 (en) New drug combinations of reboxetine and pindolol
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
ATE422498T1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
BRPI0511529A (pt) combinação terapêutica para distúrbios de hiperatividade/déficit de atenção
MY136367A (en) Treatment of cognitive failure
WO2002040006A3 (en) Treatment of anxiety disorders
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
HK1056120A1 (en) Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder.
NO20085172L (no) 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst
HUP0101748A2 (hu) Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
MXPA03006742A (es) Uso de buprenorfina para la terapia de la incontinencia urinaria.
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
BR9803615A (pt) Dispositivo amortecedor de ruìdos para discos diamantados